Parexel has announced it has signed a new master service agreement (MSA) with Pfizer Inc. This continues their decade-long partnership. The agreement is for a three-year term with an option to extend for an additional two years.
“We are pleased to have the opportunity to continue partnering with Pfizer in their mission to deliver break-through therapies for patients,” said Jamie Macdonald, Chief Executive Officer. “Pfizer’s mission aligns perfectly with Parexel’s focus on putting the patient at the heart of everything we do, and we have seen positive results from this alignment over our long-term relationship. We look forward to continuing to work with Pfizer to advance their important clinical development programs for the benefit of patients.”
Parexel will provide Pfizer clinical development services via full-service, hybrid and functional service provider (FSP) models across all therapeutic areas, including rare diseases, oncology, inflammation and immunology and internal and hospital-based medicines.
Read the full release, here.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Novel Agent Shows Superiority Over Placebo in Reducing Monthly Migraine Days
September 5th 2024Lu AG09222 shows promise as first-in-class medication that prevents neurogenic inflammation, vasodilation, and parasympathetic lacrimation, which are considered to be surrogate markers of migraine attacks.